Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 combined with jiecaxitinib hydrochloride and chemotherapy in advanced solid tumors
CTR20253351Phase 2Active
- Sponsor
- Zelgen
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig, gecacitinib in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zelgen. Started Aug 2025; status: active.
02
Drugs
nilvanstomiggecacitinib
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20253351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253351.